Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II erlotinib + bevacizumab in refractory advanced upper gastrointestinal carcinomas
2006-001308-35Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Apr 2006
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib and bevacizumab in upper gastrointestinal carcinoma, esophageal cancer, gastric adenocarcinoma and 3 more, sponsored by Rigshospitalet. Primary endpoints: Median time to progression and Response rate. Started Apr 2006; status: completed.
02
Drugs
erlotinibbevacizumab
03
Conditions
upper gastrointestinal carcinomaesophageal cancergastric adenocarcinomapancreatic cancer (PC)gallbladder cancer
Beyond the preview
Go deeper on 2006-001308-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001308-35.